Dennie Jones is an Oncology physician. ClinicalTrials.gov lists 7 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1600 SW Archer Rd
Box 100278
Gainesville, FL 326100278
Telephone
352-273-7832Registry record last updated 29 Apr 2016.
Clinical trials
- TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
Sponsor: University of Florida
- Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
Sponsor: University of Florida
- Observational Study of Best Supportive Care With or Without Surgery, Chemo or Radiotherapy in Pts With Carcinoma of Lung
Sponsor: New Mexico Cancer Research Alliance
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
54.5%Opioid Agonist30.6%Oxycodone Hcl62%Morphine Sulfate Er14%Oxycodone-Acetaminophen7%Tramadol Hcl7%Hydromorphone Hcl5%Fentanyl4%Part D<11 patientsPhenothiazine10.1%Prochlorperazine Maleate100%Part D≥80 patients+ 5 more classes in this area
Cancer & immunology
18.2%Cytochrome P450 17A1 Inhibitor6.2%Abiraterone Acetate100%Part D≥18 patientsKinase inhibitor6.1%Tagrisso31%Imbruvica24%Gilotrif17%Alecensa14%Verzenio14%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
10.1%Corticosteroid5.8%Prednisone100%Part D≥38 patientsSerotonin-3 Receptor Antagonist2.5%Ondansetron Hcl50%Ondansetron Odt50%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”